41 results about "Coccidiosis vaccine" patented technology

The invention discloses an E.tenella protein disulfide linkage isomerase gene EtPDI (Clone ID is BW1-E06,and the Genbank accession number of is EF552214). The gene is connected with a procaryon expression vector pGEX-4T-2; a procaryon expression recombination plasmid pGEX-4T-EtPDI is constructed and is expressed in a colibacillus system; and most of the expressed recombining protein exists in a soluble form. The recombining protein 4T-EtPDI is purified to carry out SPS-PAGE and is transferred to a PVDF film; and antiserum of E.tenella oocyst oral immunized chicken is used as first resistance and goat anti-chicken IgG is used as second resistance to carry out Western-blot analysis, thereby indicating that the gene has certain antigen. The gene is used for preparing an anti-chicken coccidiosis drug and an anti-chicken coccidiosis vaccine.

Disclosed herein are compositions for the treatment of a disease in an animal including yeast extract of Saccharomyces cerevisiae, Bacillus licheniformis or Bacillus subtilis spores, and a carrier. Also included are animal feed compositions including the composition for the prevention, control and/or treatment of a disease in an animal and an animal's food/feed. The compositions are useful to prevent, control, and treat diseases such as necrotic enteritis in poultry when used in combination with an anticoccidal ionophore or coccidiosis vaccine.

The invention discloses a chicken coccidiosis vaccine suspension agent and suspension fluid therewith. The chicken coccidiosis vaccine suspension agent comprises xanthan gum and aqueous ethanol, wherein the volume concentration of the aqueous ethanol is greater than 38% and smaller then or equal to 100%, and a weight-to-volume ratio of xanthan gum to aqueous ethanol is from 3% to 60%. Xanthan gum is preferably selected fromfood-grade and pharmaceutical grade xanthan gum, and ethanol is preferably selected from food-grade and pharmaceutical grade ethanol. The invention further discloses suspension fluid prepared by using the suspending agent. The invention is advantaged in that: first, the suspension agent can dissolve in water rapidly; second, prepared chicken coccidiosis live vaccine oocysts can be kept in water by the prepared suspension fluid for 8 hour without sedimentation such that quantity uniformity of vaccine oocysts drunk by chickens can be improved; third, non-water-stopping chicken flock immunization can be carried out, and water-stopping stress response is reduced; fourth, water-stopping chicken flock immunization can further be carried out, and immunization time is shortened; and fifth, a side effect of the vaccine is reduced.

A method for obtaining an immunogenic strain useful for producing a vaccine against Coccidiosis comprises the cycle of infecting at least one first group of specific pathogen-free donor birds with oocysts from an Eimeria species. Blood is then collected from these donor birds, and is then used to infect a second group of specific pathogen-free birds. Oocysts are collected from the second group of birds. These oocysts are then multiplicated to complete the cycle. The cycle is then repeated using the multiplicated oocysts. After a total of about three cycles, a final antigen may be harvested and utilized as a source to generate oocysts for a vaccine.

The invention relates to the technical field of prevention and control of livestock and poultry diseases, in particular to a live coccidiosis vaccine and application thereof. The vaccine comprises a coccidiosis virulent strain and a coccidiosis attenuating strain having the same parasitic site or having the same parasitic site at any one or more stages of the parasitic life history; in the vaccine, the oocysts number ratio of the coccidiosis attenuated strain to the coccidiosis virulent strain is 50:1-3:1. A high dose of the weakly pathogenic coccidiosis strain is used for producing a competitive occupying advantage for a highly pathogenic strain having the same parasitic site, a occupying effect of the symbiotic pathogen in vaccine components is established, and the fertility, pathogenicity and damage to a host caused by over-intake are reduced after the highly pathogenic strain is immunized as the vaccine components. The coccidiosis vaccine can effectively improve the safety of the vaccine, reduce the cost of drug prevention and control, and have a good application potential while ensuring the immune efficacy of the vaccine.

The invention relates to a preparation method and an application of a chicken manure protecting agent in production of a chicken coccidiosis vaccine. A composition comprises the following ingredientsin parts by weight: 1-10 parts of fructose, 1-10 parts of polyvinyl pyrrolidone (10%), 0.01-0.1 parts of sodium azide, 0.01-0.05 parts of sulfuric acid (98%) and 50-98 parts of sterile water. A formula composition of the agent is scientific and reasonable; a technology is simple; and the agent is convenient to use and very low in cost and has a better protecting effect on coccidian oocysts in manure. The protecting agent employing the ingredients such as the fructose serves as the protecting agent of the chicken manure in the production of the chicken coccidiosis vaccine can effectively keep activity of the coccidian oocysts in the chicken manure, prolongs preservation time of the manure, facilitates scale production and improves production efficiency. The manure preserved by the protecting agent can be preserved for 4 days at a room temperature, and the activity of the oocysts has no change as compared with that of oocysts in the fresh manure.

The invention discloses a coccidiosis oocyst cryoprotectant, and a preparation method and application thereof. The coccidiosis oocyst cryoprotectant comprises the following components: sodium dodecylsulfate, distearoyl phosphatidyl ethanolamine-polyethylene glycol, tartaric acid, ammonium sulfate, sucrose, fructose, sodium dihydrogen phosphate, disodium hydrogen phosphate, a standard PBS buffer solution and water for injection. The cryoprotectant is reasonable in formula, and can effectively inhibit ice crystal recrystallization in the cryopreservation process, regulate and control ice crystal morphology, reduce ice crystal growth rate and decrease damage of ice crystals to coccidiosis oocysts; and meanwhile, phospholipid molecules can be adsorbed to the walls of the coccidiosis oocysts,so the ice damage resistance of the coccidiosis oocysts is improved, and the coccidiosis oocysts can be stored in liquid nitrogen for a long time. Compared with a traditional cryoprotectant, the coccidiosis oocyst cryoprotectant of the invention does not contain toxic molecules such as DMSO and components such as expensive serum, avoids the toxic damage of DMSO to coccidiosis oocysts, lowers production cost, has effectively improved applicability in the field of coccidiosis vaccines is enhanced, and the cryoprotectant and is beneficial for wide popularization and application.

The invention relates to biological immunity and a vaccine, and in particular discloses a coccidiosis vaccine component having a cross immunological protection capacity and a vaccine containing the coccidiosis vaccine component. The coccidiosis vaccine component is a transgenic coccidiosis strain capable of expressing heterogeneous coccidiosis immunity dominant antigens. The transgenic coccidiosis strain, which simultaneously has immunogenicities of a parental coccidiosis strain and a heterogeneous coccidiosis strain, can enhance the cross immunological protection capacity of the coccidiosis vaccine component when the transgenic coccidiosis strain serves as the coccidiosis vaccine component. Based upon experimental studies, it discovers that the cross immunological protection capacity, which is provided by the novel vaccine component, is positively correlated to the quantity of the expressed heterogeneous dominant antigens; therefore, preferably, a plurality of immunity dominant antigens are expressed. According to the coccidiosis vaccine component and a construction strategy thereof provided by the invention, the immunological protection capacity can be offered for various insect infections; and the cross immunological protection capacity is universal.

A vaccine for in ovo vaccination against avian coccidiosis produced by a method including obtaining the coccidial oocysts from a fecal suspension, homogenizing the fecal suspension, separating the oocysts from the fecal debris by either salt flotation using sodium sulfate or gas flotation using air, sporulating the oocysts using hydrogen peroxide and air sparging, bleaching the sporulated oocysts, washing the bleached oocysts, concentrating the sterile washed oocysts and combining the concentrates of various species of coccidial oocysts, and producing a vaccine. The method in whole or in part can be applied to other kinds of encysted protozoa to produce vaccines for various types of animals.

The invention relates to the field of poultry breeding and specifically relates to a method for accurately estimating each index concentration after challenge of chicken eimeria tenella according to resistance indexes measured after immunization with a chicken coccidiosis vaccine. The method comprises the steps of immunizing samples to be screened with the chicken coccidiosis vaccine and then measuring five resistance indexes in the blood plasma, namely CAT, SOD, GSH-Px, MDA and IFN-gamma, and then accurately estimating the corresponding concentration of each index after the challenge (infection) of the chicken eimeria tenella by use of a pre-established regression equation of each resistance index according to the five resistance indexes measured after immunization with the chicken coccidiosis vaccine so as to select chicken eimeria tenella resistant individuals by use of the five resistance indexes under the condition of non-challenge (infection), wherein the regression equation of the resistance index refers to the quantitative relation of the resistance index after immunization with the chicken coccidiosis vaccine and challenge (infection). The method is capable of realizing conventional selective breeding of the chicken coccidiosis, and is safe and significant.

The invention discloses application of a plant fiber to preparation of a medicine used for preventing chicken coccidiosis. The plant fiber is applied to preparation of the medicine used for preventing chicken coccidiosis and has the advantages of edibility, large hole and strong water absorbing capacity, the plant fiber is mixed with a chicken coccidiosis vaccine, a vaccine oocyst is effectively adsorbed in a hole of the plant fiber to prepare the medicine used for preventing chicken coccidiosis, a chicken is immunized after taking the medicine used for preventing chicken coccidiosis, the immunity uniformity is good, the application is particularly suitable for preventing the chicken coccidiosis of a large-scale chicken farm, and the problem that the chicken coccidiosis of the large-scale chicken farm is difficult to prevent at present is well solved.

The invention discloses a cryoprotectant and a preparation method thereof, and application of the cryoprotectant in coccidiosis oocysts. The cryoprotectant comprises the following components: lauric acid, hydrogenated phosphatidylcholine, sodium fluoride, ammonium chloride, asparaginic acid, proline, cane sugar, sodium dihydrogen phosphate, disodium hydrogen phosphate, a PBS buffer solution and water for injection. The cryoprotectant is reasonable in formula, ice crystal recrystallization in the cryopreservation process can be effectively inhibited, ice crystal morphology is regulated and controlled, the ice crystal growth rate is reduced, and damage of ice crystals to coccidiosis oocysts is reduced; and meanwhile, phospholipid molecules can be adsorbed to the walls of the coccidiosis oocysts, so the ice damage resistance of the coccidiosis oocysts is improved, and the coccidiosis oocysts can be stored in liquid nitrogen for a long time. Compared with a traditional cryoprotectant, thecryoprotectant of the invention has the advantages that the cryoprotectant does not contain toxic molecules such as DMSO and components such as expensive serum, avoids the toxic damage of DMSO to coccidiosis oocysts, and is reduced in production cost, effectively improved in applicability in the field of coccidiosis vaccines and beneficial to wide popularization and application.

The invention discloses a construction method of a laying hen intestinal enteritis model. The construction method comprises the following steps: 40 Roman pink laying hens in the egg laying peak period are selected, and the selected Roman pink laying hens are set as a control group and four challenge treatment groups respectively; the challenge treatment groups are treatment groups of coccidiosis vaccine and A-type clostridium perfringens with different gradients, the coccidiosis vaccine is firstly fed at 9:00 in the morning every day after the test is started, and clostridium perfringens liquid is fed after half an hour; sampling is carried out 48 hours after the last time of feeding; and the test period is 7 days, feed is corn-soybean meal type basic feed, and feeding management is carried out according to conventional feeding management. According to the method, the specific mechanism of reduction of the production performance of the laying hens caused by factors such as nutrition and feed factors, stress and the like can be explored.

The invention discloses a mixture for preventing coccidiosis of indoor floor rearing meat chicken. The weight ratio of the raw material formula is white cement: industrial salt: quick lime: water=1:2:10:15. During application, after a barton is cleaned, disinfected and dried, the mixture of salt, lime, white cement and water is sprayed to the barton ground and the peripheral wall away from the ground by 30 cm or less to form a protective film, 0.5-0.6 kg of mixture is used for one square meter, the thickness is about 1 mm, and the effect of controlling coccidiosis of the meat chicken is achieved. A coccidiosis vaccine is not needed for preventing coccidiosis of the indoor floor rearing meat chicken, cost of coccidiosis medicine is saved by 0.05 yuan per chicken, the production effect is not poor than that of the method using vaccine and medicine for controlling, generated economic benefits are larger, and food safety are higher.

The invention relates to the field of biological immunity, and particularly discloses a coccidiosis-in-chicken vaccine immune method. The coccidiosis-in-chicken vaccine immune method includes the specific steps that one-day-age chickens are immunized coccidiosis vaccine through mouths for 1 day to 3 days, and then are immunized same coccidiosis vaccine. Coccidiosis-in-chicken vaccine immune is carried out with the method, the risk that oocysts are largely discharged after primary immunization to be eaten by chickens to break out coccidiosis can be effectively avoided, the uniformity coccidiosis vaccine immune can be increased to be 90% or above, the immune protection force can be also rapidly built, better protection is achieved to secondary coccidium infection, production performance reduction caused by vaccine immunity is retarded, and the culture benefits are increased. Meanwhile, the using amount of anti-coccidiosis medicine can be reduced and avoided, and safer and more environmentally friendly poultry and egg products are provided; in addition, the cost of the immune method is saved, and economic benefits are huge.